Zinc-finger proteins (ZNFs) are one of the most abundant groups of proteins and have a wide range of molecular functions. Given the wide variety of zinc-finger domains, ZNFs are able to interact with DNA, RNA, PAR (poly-ADP-ribose) and other proteins. Thus, ZNFs are involved in the regulation of several cellular processes. In fact, ZNFs are implicated in transcriptional regulation, ubiquitin-mediated protein degradation, signal transduction, actin targeting, DNA repair, cell migration, and numerous other processes. The aim of this review is to provide a comprehensive summary of the current state of knowledge of this class of proteins. Firstly, we describe the actual classification of ZNFs, their structure and functions. Secondly, we focus on the biological role of ZNFs in the development of organisms under normal physiological and pathological conditions.

Cell Death Discovery (2017) 3, 17071; doi:10.1038/cddiscovery.2017.71; published online 13 November 2017

Zinc-finger proteins (ZNFs) are one of the most abundant groups of proteins and have a wide range of molecular functions. Given the wide variety of zinc-finger domains, ZNFs are able to interact with DNA, RNA, PAR (poly-ADP-ribose) and other proteins. Thus, ZNFs are involved in the regulation of several cellular processes. In fact, ZNFs are implicated in transcriptional regulation, ubiquitin-mediated protein degradation, signal transduction, actin targeting, DNA repair, cell migration, and numerous other processes. The aim of this review is to provide a comprehensive summary of the current state of knowledge of this class of proteins. Firstly, we describe the actual classification of ZNFs, their structure and functions. Secondly, we focus on the biological role of ZNFs in the development of organisms under normal physiological and pathological conditions.

Cell Death Discovery (2017) 3, 17071; doi:10.1038/cddiscovery.2017.71; published online 13 November 2017

Non-classical types of zinc-finger differ in cysteine/histidine combinations, such as C2–H2, C2–CH, and C2–C2. Currently, 30 types of ZNFs are approved by The HUGO Gene Nomenclature Committee,9 and ZNF classification is based on the zinc-finger domain structure. A complete list of ZNF types with a description of the zinc-finger domain structure, the number of genes included, and the most studied members is summarized in Table 1. The most important and abundant types of zinc-finger domain proteins include C2H2, really interesting new gene (RING), plant homeodomain (PHD), and Lin-Il, Isl-1, and Mec-3 (LIM domains). Their protein structures are presented in Figure 1a.

Among C2H2 ZNFs, there are a large number of transcription factors with the C-x-C-H-x-H motif, which mediates direct interaction with DNA. One of the C2H2 members, ZNF217, contains multiple C2H2 domains. These domains bind a specific DNA sequence (T/A)(G/A)CAGAA(T/G/C), repressing the expression of target genes.10

The group of RING domain proteins include numerous E3-ubiquitin ligases. The RING-motif structure is C-x-C-x-C-H-x-C-x C-x-C-x-C. One of the most important E3-ubiquitin ligases, Mouse Double Minute 2 (MDM2), which is involved in cancer progression, has a RING domain. This domain mediates its interaction with itself and Mouse Double Minute 4 (MDM4). This domain is also important for E3-ubiquitin ligase activity.11

The PHD zinc-finger domains are involved in the regulation of epigenetic modifications via their chromatin-remodelling ability. The PHD motif has the following primary structure: C-x-C-x-C-x-C-H-x-C-x-C-x-C. One of the ZNFs with a PHD domain is Lysine Demethylase 2A (KDM2A), which mediates nucleosome recognition.12

The LIM-type of ZNF was identified in transcription factors Lin-Il, Isl-1, and Mec-3.13 Currently, this class of ZNFs contains proteins important for actin targeting, cytoskeleton interaction, and focal adhesion. One important member, Paxillin, has four LIM motifs. The LIM motif structure is C-x-C-x-H-x-C-x-C-x-C-x-C-(H,D).14

The zinc-finger domain of Paxillin mediates β-catenin interaction at focal adhesion sites15 and stress fibers.16

FACTS

- Zinc-finger proteins (ZNFs) are involved in several cellular processes acting through different molecular mechanisms.
- ZNFs have key role in development and differentiation of several tissues.
- ZNFs are involved in tumorigenesis, cancer progression and metastasis formation.
- Alterations in ZNFs are involved in the development of several diseases such as neurodegeneration, skin disease and diabetes.

OPEN QUESTIONS

- ZNFs may act both as oncogene or tumor suppressor gene; can restoration or depletion of ZNFs expression be a new challenge in cancer drug design?
- Could ZNFs be used as a prognostic factor for cancer, neurodegeneration, or other diseases?

ZNF STRUCTURE, CLASSIFICATION, AND MOLECULAR FUNCTIONS

The first ZNF was identified in the late 1980s. The first ZNF was Transcription Factor IIa (TFIIa) from Xenopus laevis. This gave rise to the discovery of a new group of transcriptional activator proteins with a 30 amino acid repeating region. This new class of proteins was able to bind specific sequences of DNA.1,2 The zinc-finger structure (extensively reviewed in refs 3–7) is maintained by the zinc ion, which coordinates cysteine and histidine in different combinations. In classical C2H2 zinc-finger proteins, two cysteines in one chain and two histidines in other one are coordinated by a zinc ion. Crystallographic studies revealed that classical zinc-finger domains have two β-sheets and one α-helix.8

Non-classical types of zinc-finger differ in cysteine/histidine combinations, such as C2–H2, C2–CH, and C2–C2. Currently, 30 types of ZNFs are approved by The HUGO Gene Nomenclature Committee,9 and ZNF classification is based on the zinc-finger domain structure. A complete list of ZNF types with a description of the zinc-finger domain structure, the number of genes included, and the most studied members is summarized in Table 1. The most important and abundant types of zinc-finger domain proteins include C2H2, really interesting new gene (RING), plant homeodomain (PHD), and Lin-Il, Isl-1, and Mec-3 (LIM domains). Their protein structures are presented in Figure 1a.

Among C2H2 ZNFs, there are a large number of transcription factors with the C-x-C-H-x-H motif, which mediates direct interaction with DNA. One of the C2H2 members, ZNF217, contains multiple C2H2 domains. These domains bind a specific DNA sequence (T/A)(G/A)CAGAA(T/G/C), repressing the expression of target genes.10

The group of RING domain proteins include numerous E3-ubiquitin ligases. The RING-motif structure is C-x-C-x-C-H-x-C-x C-x-C-x-C. One of the most important E3-ubiquitin ligases, Mouse Double Minute 2 (MDM2), which is involved in cancer progression, has a RING domain. This domain mediates its interaction with itself and Mouse Double Minute 4 (MDM4). This domain is also important for E3-ubiquitin ligase activity.11

The PHD zinc-finger domains are involved in the regulation of epigenetic modifications via their chromatin-remodelling ability. The PHD motif has the following primary structure: C-x-C-x-C-x-C-H-x-C-x-C-x-C. One of the ZNFs with a PHD domain is Lysine Demethylase 2A (KDM2A), which mediates nucleosome recognition.12

The LIM-type of ZNF was identified in transcription factors Lin-Il, Isl-1, and Mec-3.13 Currently, this class of ZNFs contains proteins important for actin targeting, cytoskeleton interaction, and focal adhesion. One important member, Paxillin, has four LIM motifs. The LIM motif structure is C-x-C-x-H-x-C-x-C-x-C-x-C-(H,D).14

The zinc-finger domain of Paxillin mediates β-catenin interaction at focal adhesion sites15 and stress fibers.16

1Department of Experimental Medicine and Surgery, University of Rome ‘Tor Vergata’, Rome 00133, Italy; 2Medical Research Council, Toxicology Unit, Leicester University, Leicester LE1 9HN, UK and 3ENEA Research Center Casaccia, Laboratory of Biosafety and Risk Assessment, Via Anguillarese, Rome, Italy.

Correspondence: G Raschella (giuseppe.raschella@enea.it)

Received 11 August 2017; revised 28 August 2017; accepted 29 August 2017; Edited by A Rufini
Table 1. Types of zinc-finger proteins

| Type name                        | Zinc-finger structure | Number of genes | Number of TF | Important members                                      |
|---------------------------------|-----------------------|-----------------|--------------|-------------------------------------------------------|
| Zinc fingers C2H2-type (ZNF)    | C-x-C-x-H-x-H         | 720             | 372          | KLF4, KLF5, EGR3, ZFP637, SLUG, ZNF750, ZNF281, ZBP89, GLIS1, GLIS3 |
| Ring finger proteins (RNF)      | C-x-C-x-C-x-H-xxxx-C-x-C-x-C | 275           | 12           | MDM2, BRCA1, ZNF179                                    |
| PHD domain-containing (PHD)     | C-x-C-x-H-x-C-x-C-x-C-x-C | 90             | 0            | KDM2A, PHF1, ING1                                     |
| LIM domain separating (LIM)     | C-x-C-x-C-x-C-x-C-x-C-(C,H,D) | 53             | 1            | ZNF185, LIMK1, PXXN                                   |
| Nuclear hormone receptors (NR)  | C-x-C-x-C-x-C-x-C-x-C-x-C-x-C | 50             | 47           | VDR, ESRI, NR4A                                       |
| Zinc fingers CCCH-type (ZC3H)   | C-x-C-x-C-x-H         | 35              | 2            | RC3H1, HLBZ, MBNL1, ZFP36, ZFP36L1                    |
| Zinc fingers FYVE-type (ZFYVE)  | C-x-C-x-C-x-C-x-C-x-C-x-C | 31             | 0            | EEAI, HGS, PFKFYVE                                    |
| Zinc fingers CCHC-type (ZC3HC)  | C-x-C-x-H-x-C         | 25              | 2            | CNBP, SFI, LINQ8A                                     |
| Zinc fingers DHHC-type (ZDHHC)  | C-x-C-x-H-x-C-xxxx-C-x-C-x-C-x-C | 24             | 0            | ZDHHC2, ZDHHC8, ZDHHC9                               |
| Zinc fingers MYND-type (ZMYND)  | C-x-C-x-C-x-C-x-C-x-C-x-C-x-C-x-C | 21             | 4            | PDCD2, RUNXTT1, SMYD2, SMYD1                         |
| Zinc fingers RANBP2-type (ZRANB)| C-x-C-x-C-x-C         | 21              | 3            | YAF2, SHARPIN, EWSR1                                 |
| Zinc fingers ZZ-type (ZZZ)      | C-x-C-x-C-x-C         | 18              | 3            | HERC2, NBR1, CREBBP                                  |
| Zinc fingers C2HC-type (ZC2HC)  | C-x-C-x-H-x-C         | 16              | 2            | IKBGK, L3MBTL1, ZNF176                                |
| GATA zinc-finger domain containing (GATAD) | C-x-C-x-C-x-C | 15             | 15           | GATA4, GATA6, MTA1                                   |
| ZF class homeboxes and pseudogenes | C-x-C-x-H-x-H      | 15              | 10           | ADNP, ZEB1, ZHX1                                     |
| THAP domain-containing (THAP)   | C-x-C-x-H-x-C         | 12              | 3            | THAP1, THAP4, THAP11                                 |
| Zinc fingers CXXC-type (CXXC)   | C-x-C-x-C-x-C-xxxx-C-x-C-x-C-x-C | 12             | 2            | CXXC1, CXXC5, MBD1,DNMT1                             |
| Zinc fingers SWIM-type (ZSWIM)  | C-x-C-x-H-x-C         | 9               | 0            | MAP3K1, ZSWIM5, ZSWIM6                               |
| Zinc fingers AN1-type (ZFAND)   | C-x-C-x-C-x-C-xxxx-C-x-C-x-C-x-C-x-C-x-C | 8             | 0            | ZFAND3, ZFAND6, IGHMBP2                              |
| Zinc fingers 3CXXC-type (Z3CXXC)| C-x-C-x-H-x-C         | 8               | 0            | ZARI, RTP1, RTP4                                     |
| Zinc fingers CW-type (ZCW)      | C-x-C-x-C-x-C         | 7               | 0            | MORC1, ZCWPW1, KDM1                                 |
| Zinc fingers GRF-type (ZGRF)    | C-x-C-x-C-x-C         | 7               | 0            | TTF2, NEIL3, TOP3A                                   |
| Zinc fingers MIIZ-type (ZMIZ)   | C-x-C-x-H-x-C         | 7               | 1            | PIA51, PIA33, PIA54                                  |
| Zinc fingers BED-type (ZBED)    | C-x-C-x-H-x-C         | 6               | 2            | ZBED1, ZBED4, ZBED6                                  |
| Zinc fingers HIT-type (ZNHIT)   | C-x-C-x-C-x-C-xxxx-C-x-C-x-C-x-C-x-C | 6             | 0            | ZNHIT3, DDX59, INO80B                               |
| Zinc fingers MYM-type (ZMYM)    | C-x-C-x-C-x-C         | 6               | 6            | ZMYM2, ZMYM3, ZMYM4                                  |
| Zinc fingers matrin-type (ZMAT) | C-x-C-x-H-x-H         | 5               | 0            | ZNF638, ZMAT1, ZMAT3, ZMAT5                          |
| Zinc fingers C2H2C-type         | C-x-C-x-H-x-H         | 3               | 3            | MYT1, MYT1L, ST18                                    |
| Zinc fingers DBF-type (ZDBF)    | C-x-C-x-H-x-H         | 3               | 0            | DBF4, DBF4B, ZDBF2                                   |
| Zinc fingers PARP-type          | C-x-C-x-H-x-C         | 2               | 1            | LIG3, PARP1                                          |
Interestingly, many ZNFs contain multiple and different types of zinc-finger domains (Figure 1b). For example, two lysine demethylases, Lysine Demethylase 4A (KDM4A), a novel target for antitumor therapy, and KDM2A, which is required for DNA damage response, exhibit different zinc-finger compositions. Nevertheless, an important acetyltransferase, Lysine Acetyltransferase 6A (KAT6A), which regulates cell cycle progression, has the same zinc-finger pattern as KDM4A but exhibits a different molecular function. Furthermore, RANBP2-Type and C3HC4-Type Zinc-Finger Containing 1 (RBCK1), Ubiquitin Like With PHD And Ring Finger Domains 1 (UHRF1), and Roquin-1 contain a RING-type zinc-finger domain that possesses E3-ubiquitin ligase activity. These proteins also possess additional different zinc-finger domains. For example, RBCK1 contains a RAN-binding protein 2 (RanBP2) domain and has an important role in the immune response. UHRF1 also contains a PHD domain that is important for its repressive activity on gene promoters. Finally, Roquin-1 possesses a C3H1 domain that targets RNA.

Gene ontology analysis of 1723 annotated human ZNFs revealed that this class of proteins has numerous functions (Figure 1c). ZNFs localize in different cell compartments (Figure 1d). Indeed, chromatin-remodelling ZNFs (for example, KDM2A, Lysine Methyltransferase 2B (KMT2B) and AT-Rich Interaction Domain 2 (ARID2)) and transcription factors (for example, ZNF750, Kruppel Like Factor 4 (KLF4) and GATA Binding Protein 2 (GATA2)) are localized in the nucleus. Cbl Proto-Oncogene (CBL) and TNF Receptor Associated Factor 4 (TRAF4) are membrane proteins. MDM2, Praja Ring Finger Ubiquitin Ligase (PJA2), and Autocrine Motility Factor Receptor (AMFR) belong to the E3-ubiquitin ligase family are mainly localized in the cytoplasm. However, MDM2 has been also show to localize in the nucleus. Rho/Rac Guanine Nucleotide Exchange Factor 2 (ARHGEF2) and Actin-Binding LIM Protein 1 (ABLIM1) are associated with the cytoskeleton, and Paxillin with ZNF185 is localized to focal adhesion sites.

The zinc-finger domain is one of the most frequently utilized DNA-binding motif found in eukaryotic transcriptional factors. The binding of a zinc-finger domain to its target site juxtaposes three base pairs on DNA to a few amino acids in the α-helix structure. The identity of the aminonoacids at the contact site defines the DNA sequence recognition specificity of zinc fingers. Thus, by changing these amino acids, a high degree of selectivity can be achieved toward a given three base-pair DNA sequence. Exploiting this recognition mechanism, protein modules containing multiple zinc-finger motifs, each one recognizing a specific three base-pair DNA sequence, have been engineered which bind to specific DNA sequences. Fusing this recognition module with a sequence-independent endonuclease was the first successful strategy to introduce breaks at specific sites of genomic DNA. Precise genome editing was more recently achieved with other
techniques based on transcription activator-like effector nucleases (TALEN)<sup>29</sup> and clustered regularly interspaced short palindromic repeats (CRISPR) Cas9<sup>30</sup> whose description is beyond the scope of this review.

**PHYSIOLOGICAL ROLE OF ZNFs**

**Skin**

Through their ability to regulate gene expression, ZNF proteins participate in numerous physiological processes, including cell proliferation, differentiation, and apoptosis, thereby maintaining tissue homeostasis. For example, a recent study suggested that the zinc-finger proteins ZFP36 (RING-type, not transcription factor) an RNA binding protein, also known as Tristetrapolin<sup>31</sup> and ZFP36L1 have a key role in the regulation of several aspects of keratinocyte biology, such as cell proliferation, differentiation and apoptosis. In fact, inhibition of the expression of these two proteins in cultured keratinocytes caused apoptosis and cell cycle arrest at the G2/M phase. In addition, Zfp36 knockdown in these cells also results in increased expression of the differentiation marker Keratin 10, suggesting the possible involvement of this protein in keratinocyte differentiation.<sup>32</sup>

Another zinc-finger protein that has a crucial role in keratinocyte differentiation, is the transcription factor, KLF4 (C2H2-type, transcription factor).<sup>33</sup> Indeed, in the epidermis, KLF4 is mainly expressed in suprabasal layers, where it modulates the expression of genes involved in keratinocyte differentiation (ECM1, SPINK5, CDSN, FLG, and LCE3)<sup>34</sup> (Figure 2a). In Klf4<sup>−/−</sup> mice, the absence of this ZNF protein results in altered skin barrier formation, causing embryonic death soon after birth.<sup>35</sup> Conversely, the ectopic expression of KLF4 in basal keratinocytes of transgenic mice epidermis accelerates the differentiation process, resulting in early epidermal barrier formation.<sup>36</sup>

The zing-finger protein ZNF750 (C2H2-type, transcription factor) also acts as an essential regulator of keratinocyte differentiation. During epidermal differentiation, TP63 expression regulates ZNF750 expression, which subsequently directly activates KLF4 expression.<sup>37</sup> However, more recently, a layer of complexity has been added to the underlying mechanism by which ZNF750 regulates terminal differentiation of keratinocytes. ZNF750 represses the expression of progenitor genes (RBBP8, HOMER3) by interacting with the chromatin modifiers REST corepressor 1 (RCOR1), lysine demethylase 1A (KDM1A) and C-terminal binding protein 1/2 (CTBP1/2) and activates differentiation genes (PPL, PKP1) by interacting with RCOR1, KLF4, and CTBP1/2.<sup>38</sup> (Figure 2a). Interestingly, as described below, alteration of ZNF750 transcriptional regulation network during keratinocyte differentiation, caused by ZNF750 mutations, is involved in the development of diseases, such as psoriasis.<sup>39,40</sup>

**Intestine**

ZNF proteins are also involved in intestinal epithelium biology. For example, in addition to its well-documented role in skin homeostasis, KLF4 also has a key role in the intestines. In this tissue, KLF4 is expressed in the terminally differentiated epithelial cells (luminal surface) and goblet cells (crypts), where it promotes differentiation and inhibits proliferation.<sup>41–44</sup> In particular, KLF4 represses intestinal epithelium proliferation by interacting with β-catenin and inhibiting β-catenin-mediated gene expression (Figure 2b). In addition, Klf4<sup>−/−</sup> mice lack goblet cells, indicating that KLF4 has an essential role in goblet cell differentiation.<sup>45</sup>

Another Krüppel-like factor, KLF5 (C2H2-type, transcription factor), is crucial for regulation of proliferation in the intestinal epithelium, exerting an opposing function to KLF4.<sup>46</sup> KLF5, which is expressed in basal epithelial cells of the crypts, is activated by the Wnt signalling pathway, promoting cell proliferation.<sup>47</sup>

Figure 2. Molecular pathways regulated by ZNFs in physiological conditions. (a) ZNF750 regulates keratinocytes terminal differentiation by interacting with KLF4 and chromatin regulators. This interaction leads to the positive regulation of genes (PPL, PKP1) involved in differentiation. In addition, ZNF750 interacts with KDM1A and negatively regulates progenitor gene expression (RBBP8, HOMER3). ZNF750 directly regulates the expression of KLF4, which subsequently modulates the expression of the indicated genes. (b) KLF4 regulates epithelial cell differentiation by interacting with β-catenin and repressing the WNT signalling pathway. (c) KLF5 is involved in myoblast differentiation, acting as a co-factor for MyoD. This action leads to the upregulation of the indicated genes. (d) The presence of SLUG on the PPARG promoter reduces HDAC1 recruitment, leading to C/EBP-mediated activation of PPARG expression. This effect promotes adipogenesis.
The GATA family members GATA4 (GATA-type, transcription factor) and GATA6 (GATA-type, transcription factor) have important roles in differentiation and homeostasis of the small intestinal epithelium. GATA4 expression is detected in the proximal but not the distal small intestine, having an important role in the maintenance of jejunal-ileal specifications. Indeed, in the jejuna of inducible intestine-selective GATA4 knockout mice, the inactivation of GATA4 results in downregulation of genes specifically expressed in the jejunum and increased expression of specific ileum genes.\(^46\) GATA6 is expressed in the entire small intestine, where is required for intestinal proliferation, secretory cell differentiation and absorptive enterocyte gene expression.\(^47\)

Muscle

ZNFs have a regulatory function in muscle differentiation. For example, SET and MYND Domain Containing 1 (SMYD1), which is specifically expressed in striated muscle, acts as an essential regulator of myogenesis.\(^48\) SMYD1 (MYND-type, not transcription factor) deletion impaired myoblast differentiation, decreasing myofibre formation and reducing muscle-specific gene expression. Moreover, inhibition of KLF5 expression in cultured C2C12 myoblasts suppresses myotube formation, suggesting that this zinc-finger protein is required for myogenic differentiation. In particular, at a molecular level, KLF5 promotes myoblast differentiation into myotubes by recruiting MyoD to muscle-specific target genes (MYOG, MYBPH, MYL4, and MYOM2)\(^49\) (Figure 2c). Further examples of zinc-finger proteins involved in the regulation of skeletal myogenesis include CXXC Finger Protein 5 (CXXC5) and Early Growth Response 3 (EGR3). In fact, CXXC5 facilitates myocyte differentiation by positively regulating skeletal muscle differentiation genes,\(^50\) whereas EGR3 promotes myoblast proliferation by stimulating nuclear factor kappa B (NF-\(\kappa\)B) signaling.\(^51\) By contrast, myogenic cellular differentiation is negatively regulated by murine zinc-finger Zfp637 (C2H2-type, not transcription factor). Although its transcriptional activity has not been fully investigated, Zfp637 overexpression inhibits differentiation and promotes proliferation of myoblasts, potentially regulating murine telomerase reverse transcriptase (mTERT) expression.\(^52\)

Adipose tissue

Recent studies revealed an increased number of ZNFs as key transcriptional regulators involved in adipogenesis.\(^53\) For example, ZNF638 (Matrin-type, not transcription factor) seems to positively regulate this process given that its expression increases during preadipocyte differentiation. Indeed, ectopic expression of ZNF638 results in increased adipogenesis in vitro. On the other hand, inhibition of ZNF638 expression decreases differentiation by inhibiting the expression of adipocyte-specific genes. Specifically, ZNF638 promotes adipogenesis by acting as a transcriptional co-factor of CCAAT/enhancer-binding protein (C/EBP) and results in...
the expression of peroxisome proliferator-activated receptor γ (PPARG), which regulates adipocyte differentiation.5,54,55

The transcription factor SLUG (C2H2-type, transcription factor) is also involved in adipocyte differentiation in vitro and in vivo.56 Indeed, SLUG knockout mice exhibit decreased white adipose tissue (WAT) mass compared with wild-type mice, whereas the WAT size is increased in Slug-overexpressing mice. Accordingly, SLUG-deficient mouse embryonic fibroblasts (MEFs) exhibit impaired adipogenesis compared with wild-type MEFs. SLUG potentially controls WAT development by affecting Histone deacetylase 1 (HDAC1) recruitment to the PPARG promoter, favouring a more accessible chromatin state for PPARG transcriptional activators (Figure 2d).

In contrast to ZNF638 and SLUG, the GATA transcription factors GATA2 (GATA-type, transcription factor) and GATA3 (GATA-type, transcription factor) act as negative regulators of adipocyte differentiation.57 Indeed, their expression is detected in preadipocytes and is decreased during differentiation. Consistently, the ectopic expression of GATA2 and GATA3 in preadipocytes inhibits their transition to adipocytes by binding to the PPARG promoter, inhibiting PPARG expression. In addition, GATA2 and GATA3 also interact with C/EBPα and C/EBPβ, suppressing their transcriptional activities. Both molecular mechanisms are required to negatively regulate adipogenesis.

Cellular stemness regulation

In mice, Zfp281 (C2H2-type, transcription factor), the murine homolog of ZNF281, has an important role in regulating cellular stemness by binding the promoter of Nanog and inhibiting its transcription.58 Further work demonstrated that Nanog transcriptional repression requires the coordinated activity of NANOG itself and Zfp281, which recruits the NuRD repressor complex.59 Functionally, modulation of Nanog expression by Zfp281 is an efficient mechanism to fine-tune reprogramming activity in stem cells.

ROLE OF ZNF5 IN DISEASES

Tumour suppressor and oncogenic functions of ZNFs

Recent findings have highlighted the importance of ZNFs in cancer onset and progression. The zinc-finger family includes both tumour suppressor genes and oncogenes.60,61 ZNFs are involved in all the principal pathways of cancer progression from carcinogenesis to metastasis formation. Furthermore, ZNFs are involved in cancer via their transcription factor function. In addition, emerging evidence indicates the importance of zinc-finger proteins as recruiters of chromatin modifiers or as structural proteins that regulate cancer cell migration and invasion.

ZNF281. In recent years, several experimental studies revealed a role of ZNF281 (C2H2-type) in tumorigenesis and tumour invasion. ZNF281 is involved in two crucial processes in cancer: the DNA damage response (DDR)62–65 and the epithelial–mesenchymal transition (EMT). ZNF281 expression is increased upon DNA damage induced by drugs in several cancer types. In particular, the expression of several proteins involved in the DDR, including XRCC2, XRCC4, and Nucleolin, is regulated by ZNF281.66 Interestingly, two molecular mechanisms have been proposed: i) ZNF281 acts as transcription factor and directly regulates the transcription of XRCC2 and XRCC4; ii) ZNF281 also indirectly regulates Nucleolin expression, acting as a co-factor of c-Myc and producing an additive effect67 (Figure 4c).

Moreover, ZNF281 has also a role in metastasis in colorectal cancer (CRC) through regulation of the EMT68 (Figure 4a). During the EMT, ZNF281 expression is induced by SNAIL and inhibited at the post-transcriptional level by miR-34a.68–70 The expression of miR-34a is subsequently promoted by p53, indicating that ZNF281 in CRC is controlled by a feedback loop (Figure 4c). In addition, modulation of ZNF281 expression in CRC regulates the EMT through the activation of SNAIL expression. However, ZNF281 can also directly bind the promoters of EMT effector genes, such as CDH1, OCLN, and CLDN7 (Figure 3c). Interestingly, ZNF281 expression was upregulated in patient tumour samples, confirming an important role of ZNF281 in CRC. These data strongly suggest that ZNF281 acts as an oncogene by regulating metastasis.

ZNF750. ZNF750 is another member of the family that is involved in cancer. Indeed, ZNF750 has been described as tumour suppressor gene in squamous cell carcinomas (SCCs) of the oesophagus, lung and cervix.71,72 ZNF750 is mutated in SCCs, and truncation and missense mutations represent the most common mutations. These mutations are located in the C2H2 zinc-finger domain, suggesting the importance of the zinc-finger domain in mediating the tumour suppressor activity of ZNF750. In addition, ZNF750 is expressed at much lower levels in SCC patients compared with normal tissue. Hence, ZNF750 overexpression in vitro inhibits cell proliferation and migration (Figure 4b). Interestingly, overexpression of the C2H2 ZNF750 mutant is not able to suppress tumour growth, demonstrating that the C2H2 zinc-finger domain is essential for the tumour suppressor activity of ZNF750. At the molecular level, ZNF750 regulates a set of genes involved in cell migration, proliferation and adhesion. Particularly,
ZNF750 directly induces the expression of the long non-coding RNA TINCR, through which it regulates cancer cell proliferation and tumour growth and represses the expression of LAMC2, a component of Laminin-332. Collectively, these actions regulate cancer cell migration\textsuperscript{73,74} (Figure 3d). Accordingly, low expression of ZNF750 has been observed in head and neck SCC and lung SCC patient datasets, and this expression pattern is associated with poor prognosis. Moreover, high levels of ZNF750 are associated with a good response to chemoradiotherapy, suggesting that ZNF750 could serve as a novel candidate biomarker for chemoradiotherapy sensitivity.\textsuperscript{75}

ZNF185. ZNF185 (LIM-type, not transcription factor) is a zinc-finger protein that contains a LIM domain necessary for protein–protein interactions and an ATD (Actin Targeting Domain) domain with actin-binding activity.\textsuperscript{76} Proteins that contain LIM domains can be localized both in the nucleus and cytoplasm, exerting their molecular function through protein–protein interactions rather than DNA binding. The importance of ZNF185 in cancer progression is highlighted by its reduced expression in intermediate, high-grade, and metastatic prostate tumours compared with normal tissue. Interestingly, ZNF185 expression is reduced in prostate cancer owing to DNA methylation. In fact, prostate cancer cell lines treated with a DNA Methyl Transferase 1 (DNMT1) inhibitor exhibit increased ZNF185 expression.\textsuperscript{77} Indeed, deregulation of ZNF185 expression seems to be a recurring event in different human cancers, including prostate cancer, primary lung tumours, colon cancer and HNSCC.\textsuperscript{78,79} These data suggest a putative tumour suppressor function for ZNF185 by regulating cell proliferation and differentiation.\textsuperscript{80} Moreover, in lung cancer, BRG1, a component of the human switch/sucrose non-fermenting complex (SWI/SNF), regulates ZNF185 expression (Figure 4c). A possible mechanism by which ZNF185 exerts its function in cancer biology is through the interaction with actin filaments. Indeed, ZNF185 is associated with multiple actin-regulated structures, such as focal adhesion sites, and possesses growth inhibitory activity (Figure 3a). Localization of ZNF185 to the actin–cytoskeleton is mediated via its ATD domain, which is also required for its growth-suppressing activity. Furthermore, in prostate cancer, in addition to actin stress fibres, ZNF185 co-localizes with several cytoskeletal-related components, such as focal adhesion sites and filopodia/famellipodia.\textsuperscript{81} These data suggest that ZNF185 may act as a novel tumour suppressor gene, having a key role in cancer onset and progression.

ZBP89. ZBP89 (C2H2-type, transcription factor), also known as ZNF148, is a well-characterized zinc-finger factor involved in cancer growth and apoptosis. Indeed, several tumours, such as breast cancer, melanoma and gastric cancer, exhibit increased ZBP89 expression compared with normal tissues, suggesting an oncogene function for ZBP89.\textsuperscript{82}–\textsuperscript{84} However, ZBP89 may act as tumour suppressor gene in colorectal cancer by repression cell proliferation and inducing apoptosis.\textsuperscript{85,86} ZBP89 exerts its molecular function via two different mechanisms. First, it may act as an autonomous transcription factor by regulating the expression of MMP3\textsuperscript{87} (Matrix Metallopeptidase 3) (Figure 3e) a protein involved in tumour development and metastasis. Second, ZBP89 inhibits ODC (Ornithine Decarboxylase)\textsuperscript{88} and Vimentin\textsuperscript{89} expression through recruitment of HDAC1 to the promoter of these genes\textsuperscript{92,93} (Figure 3e). ODC is involved in tumour development, and Vimentin has a role in cell migration and invasion. These findings suggest a role for ZBP89 in the inhibition of both neoplastic transformation and metastasis formation. Moreover, ZBP89 facilitates the recruitment of HDAC3 to the promoter of CDKN2A to restrain cellular senescence, facilitating lung cancer cell proliferation.\textsuperscript{94} Recently, it has been demonstrated that ZBP89 regulates the β-catenin pathway, supporting the hypothesis that ZBP89 is involved in cancer metastasis. Indeed, in colorectal cancer, the binding of ZBP89 to the promoter of CTNNB (β-catenin) results in increased gene expression. Interestingly, the inhibition of β-catenin expression resulted in a strong reduction in ZBP89 protein expression (Figure 4d). These data suggest that β-catenin accumulation initiates a cell proliferation program through the activation of its target genes, including Zbp89. Furthermore, the induction of ZBP89 contributes to sustaining β-catenin levels, further promoting cancer cell proliferation.\textsuperscript{95}

MDM2. MDM2 (RANBP2-type; RING-motif, not transcription factor) is a zinc-finger protein that does not act as a transcription factor. Nevertheless, MDM2 has a very important role in tumour biology (extensively reviewed in Oliner et al.\textsuperscript{96}). Its importance in cancer is attributed to its regulatory function on the tumour suppressor activity of p53. Indeed, MDM2 regulates p53 activity via three different mechanisms. First, given that MDM2 exhibits E3-ubiquitin ligase activity, it can ubiquitinate p53 to promote its proteasomal degradation. Second, MDM2 interacts with p53 to prevent the binding of p53 to its target genes, which mediate the tumour suppressor function of p53.\textsuperscript{97,99} Third, MDM2 binds to the N-terminus of p53, promoting the translocation of p53 into the cytoplasm and therefore blocking the activation of p53 target genes (Figure 3f).\textsuperscript{100–102} The importance of MDM2 in tumorigenesis is also provided by overexpression experiments. In fact, MDM2 overexpression induces spontaneous tumour formation.\textsuperscript{103,104} In addition, analysis of 28 tumour types performed on approximately 4000 patients revealed that the MDM2 gene is amplified in 7% of human cancers.\textsuperscript{105} Particularly, the percentage of MDM2 amplification is increased in liposarcomas (> 80%), osteosarcomas (16%), soft tissue tumours (20%), and oesophageal carcinomas (13%).\textsuperscript{106} Moreover, point mutations affecting the zinc-finger of MDM2 have been described in human tumours.\textsuperscript{107} In vitro experiments show that these mutations disrupt the interaction of MDM2 with the ribosomal protein L5 and L11 and the ability to degrade p53.\textsuperscript{108} Given its importance, MDM2 is considered a putative target for therapies. An effort has been made to develop compounds that may prevent the interaction between MDM2 and p53, blocking the oncogenic activity of MDM2.\textsuperscript{109} As extensively reviewed by Wang et al.,\textsuperscript{110} three compounds (RG7112, RG7388 and SAR405838) exhibited relevant anti-tumoural activity in patients with p53 wild type in phase I clinical trials. Given that the anti-cancer activity of these compounds is attributed to the activation of wild type p53, and these compounds are expected be effective only in patients with wild type p53.\textsuperscript{111}

ZEB1. ZEB1 (C2H2-type, transcription factor) is one of the most important zinc-finger proteins involved in tumour invasion and metastasis. Indeed, ZEB1 is one of the master regulators of the EMT\textsuperscript{112} (extensively reviewed in Zhang et al.\textsuperscript{113}). ZEB1 expression is regulated by several signalling pathways, such as Wnt, TGF-β, NF-κB, and HIF signalling, and miRNA.\textsuperscript{114} The oncogenic role of ZEB1 is due to the repression of E-Cadherin expression, which is one of the most important cell–cell adhesion proteins. ZEB1 exerts its molecular function on E-Cadherin by interacting with several chromatin-remodelling factors, such as CBP\textsuperscript{115} and the SWI/SNF complex.\textsuperscript{116} On the other hand, ZEB1 also directly activates the promoter of genes involved in the EMT. ZEB1 interacts with SMAD protein or with p300/P/CAF and activates TGF-β responsive genes to promote the EMT.\textsuperscript{117,118} Among ZEB1-activated genes, CDH2 (N-cadherin), a mesenchymal cadherin, is important in cancer progression (Figure 3b) given that altered expression of ZEB1 is observed in several human cancers, including pancreatic cancer, lung cancer, liver cancer, osteosarcoma, breast cancer, and colon cancer.\textsuperscript{109,119–122} Furthermore, the overexpression of ZEB1 in several cancer lines induces the EMT and promotes cell invasion.\textsuperscript{113,124}
ZNF family members in neurodegenerative diseases

ZPR1. In recent years, ZNFs have been demonstrated to have an important role in the pathogenesis of neuronal diseases. Spinal muscular atrophy (SMA) is a rare neuromuscular disorder characterized by loss of α-motor neurons in the anterior horn of the spinal cord and progressive muscle wasting, often leading to early death. The cause of the disease is a mutation in the Survival Motor Neurons 1 (SMN1) gene that results in reduced expression of the full-length SMN protein, which is necessary for survival of motor neurons. The first evidence of a possible involvement of ZPR1 (C4-type, not transcription factor) in SMA came from the experimental observation that the SMN protein interacts with ZPR1. The consequence of this interaction is a redistribution of the complex from the cytoplasm to the nucleus. Interestingly, this process is hampered in patients affected by SMA type I. In addition, this observation is also corroborated by evidence demonstrating that ZPR1 is expressed at low levels in patients with severe SMA. Furthermore, it has been reported that, mutation of ZPR1 resulted in embryonic lethality in mice. Moreover, the reduction of ZPR1 expression in mice, results in increased loss of spinal motor neuron, a similar phenotype observed in mice with reduced Smn gene, suggesting that the lower ZPR1 expression observed in SMA patients, can contribute to the gravity of SMA.

ZNF179. Zinc-Finger Protein 179 (ZNF179) (C4-type, not transcription factor) belongs to the RING finger class, and its expression is restricted in the brain, suggesting a possible role in the central nervous system. Indeed, inhibition of ZNF179 expression reduced neuronal differentiation in P19 cells and primary culture of cerebellar granule cells by inhibiting cell cycle progression through the regulation of p35 expression and the accumulation of p27 protein. More recently, it has been shown that ZNF179 has an anti-apoptotic role in astrocytes derived from the mouse APPtg model of Alzheimer’s disease. This effect is in part due to the inhibition of IGBP3 and BIK expression.

ZNF746. Recently, a novel role for ZNF746 (C2H2-type, not transcription factor), also known as Parkin Interacting Substrate (PARIS), has been identified in the pathogenesis of Parkinson’s disease (PD). Human ZNF746 is a protein that contains C2HC and C2H2-type zinc-finger domains at the C-terminus. This protein is regulated by the proteasome system, in particular by ubiquitination mediated by Parkin, an E3-ubiquitin ligase. PD-associated mutations in the PARK2 gene lead to the loss of its E3 ligase function, resulting in ZNF746 accumulation in human PD brain, and overexpression of the GATA4 transcription factor. The expression of SEMA3C and its receptor PLXNA2 is downregulated by GATA6 mutations, resulting in the development of OFT defects associated with CHDs.

ZNFs in other human diseases

ZNF750. Increasing evidence confirms the important roles of ZNFs in psoriasis. Psoriasis is a chronic inflammatory disorder of the skin, which varies in severity and clinical manifestations. ZNF750 is associated with a seborrhea-like dermatitis with psoriasis-like forms. In particular, the p65/p50 mutation in ZNF750 has been identified in psoriasis patients and results in a frameshift mutation. This mutation leads to the production of a truncated protein that does not contain the zinc-finger domain. Downregulation of ZNF750 leads to reduced expression of genes involved in epidermal differentiation and skin barrier formation, such as Filaggrin (FLG), Loricrin (LOR), serine protease inhibitor Kazal-type 5 (SPINK5), Arachidonate 12-Lipoxygenase, 12R Type (ALOX12B) and desmoglein1 (DSG1) (Figure 5b). These genes are mutated in various human skin diseases. In fact, the clinical manifestations of skin diseases derived from ZNF750 human mutations result from a combination of mutations in some of those downstream genes. ZNF750 and its downstream genes could be important targets for the treatment of skin diseases.

GLIS1. Gli-similar protein 1 (GLIS1) (C2H2-type, transcription factor) is Krüppel-like zinc-finger protein involved in the pathogenesis of psoriasis. Indeed, GLIS1 is significantly overexpressed in psoriatic epidermis. GLIS1 mRNA is present only in the suprabasal layers of psoriatic skin, whereas normal human epidermis does not express GLIS1. These data suggest that GLIS1 that could be involved in the regulation of abnormal
differentiation observed in psoriatic epidermis. Consistently, microarray analysis reveals that ectopic expression of GLIS1 transcriptionally regulates the expression of several genes involved in the differentiation of epidermal keratinocytes, including \(\text{S100A9}, \text{KLK7}\), small proline-rich proteins (SPRRs), involucrin (\(\text{IVL}\)), and transglutaminase 1 (\(\text{TGM1}\)) (Figure 5c). GLIS1 contains both a repressor domain at its amino terminus and an activation domain at its carboxy terminus, resulting in both transcriptional repressor and transactivator functions. GLIS1 regulates transcription of target genes through binding to oligonucleotides containing the Gli-binding site consensus sequence, GACCACCCAC, as demonstrated by electrophoretic mobility shift assays. In addition, GLIS1 is expressed in different temporal and spatial patterns during the embryonic development, thus regulating gene expression at different stages of the developmental process as demonstrated by whole mount in situ hybridization studies performed on mouse embryos.\(^{136}\)

**GLIS3.** Several reports indicate that the ZNF family might have a role in the development of diabetes. For example, GLIS3 (C2H2-type, transcription factor), a member of Kruppel-like Zinc-Finger proteins, is highly expressed in human pancreatic B-cells, and mutations in the GLIS3 gene have been identified in neonatal diabetes and congenital hypothyroidism (NDH).\(^{137}\) A human GLIS3 mutation that results in a truncated protein at its C-terminal domain has been identified, but the specific mechanism by which this mutation leads to the development of NDH has not been investigated to date. GLIS3 modulates the expression of the insulin through both direct and indirect mechanisms: binding to the\(\text{INS}\) promoter (Figure 5d) or modulating the activity of other \(\beta\)-cell-enriched transcription factors, such as\(\text{MafA}, \text{Nkx6-1}, \text{and Pax6}\). Recently, a GLIS3-deficient (\(\text{Glis3}^{-/-}\)) mouse model has been generated, exhibiting high blood sugar levels, pancreatic defects and premature death. These phenotypes resemble human neonatal diabetes caused by GLIS3 mutations.\(^{138}\) This murine model could be very useful for studying novel therapeutic applications in human diabetes. Novel clinical manifestations for patients with neonatal diabetes caused by GLIS3 mutations have been identified, such as osteopenia associated with skeletal deformity and fractures, bilateral sensorineural deafness and exocrine pancreatic dysfunction. These clinical features were not previously described, demonstrating great variability in GLIS3 mutated phenotype given that different genetic mutations result in tissue-specific expression of\(\text{GLIS3}\) mRNA.\(^{139}\)

**GATA4.** ZNFs are involved also in the pathogenesis of congenital heart diseases (CHDs). CHDs are the most common developmental anomaly affecting new-borns. For example, GATA4 is essential for proper cardiac morphogenesis. Indeed, GATA4 mutations are implicated in human congenital heart disease. A heterozygous\(G296S\) missense mutation of\(GATA4\) has been identified\(^{140}\) that causes reduced transcriptional activity and DNA-binding affinity of\(GATA4\). Furthermore, the\(GATA4\) mutation prevents the physical interaction between\(GATA4\) and\(Tbx5\), a T-box protein responsible for a subset of syndromic cardiac septal defects.\(^{141,142}\) Overexpression of\(GATA4\) is associated with cardiac hypertrophy, where directly it regulates the expression of several cardiac specific proteins, such as troponin C and I and myosin light chain-3 (Figure 5e). Interestingly, these genes are induced during cardiac hypertrophy.\(^{143}\) In addition, expression of several other proteins, including Na+/Ca\(^{2+}\)-exchanger, acetylcholine receptor-M2, cardiac-restricted ankyrin repeat protein (CARP), and adenosine receptor-A1 and carnitine palmitoyltransferase-1B, is regulated by\(GATA4\).\(^{144,145}\) These findings suggest that\(GATA4\) transcription factors could be an attractive therapeutic target for the treatment of cardiovascular diseases.

**GATA6.** Another GATA zinc-finger transcription factor expressed in the developing heart is\(GATA6\). Mutations in this gene have been identified in patients with CHDs.\(^{146}\) Recent studies demonstrated that downregulation of\(GATA6\) in neural crest-derived smooth muscle causes defects of the cardiac outflow tract (OFT) and in aortic arch arteries.\(^{147,148}\)\(GATA6\) regulates neurovascular guiding molecule semaphorin 3C (SEMA3C) and its receptor plexin A2 (\(\text{PLXNA2}\)) expression (Figure 5f), which is important for a normal OFT.\(GATA6\) mutations result in downregulation of these genes, disrupting semaphorin–plexin signalling and contributing to OFT defects, which accounts for 30% of CHDs.

Similar to\(GATA4\),\(GATA6\), and\(Tbx5\) are co-expressed in the embryonic heart, and their interaction is necessary to activate the atrial natriuretic factor promoter during cardiac morphogenesis. The interaction between the\(GATA\) family of transcription factors and\(Tbx5\) is necessary for proper cardiac function. Indeed, mutations in\(GATA4, GATA6\), and\(Tbx5\) genes disrupt these interactions, contributing to the pathogenesis of CHDs.\(^{149}\)

These data contribute to the identification of\(GATA\) mutations as a major genetic cause of CHDs.

**CONCLUSIONS**

It is now well accepted that ZNFs have a crucial role both in tissue homeostasis and disease. Interestingly, although this class of proteins was initially classified as transcription factors, several studies have highlighted novel functions of ZNFs. In fact, it has been shown that ZNFs could also act as recruiters of chromatin modifiers, as co-factors, or as structural proteins involved in cell migration and invasion.

In particular, the role of ZNFs in cancer development, progression and metastasis is becoming an interesting research issue. In fact, ZNF expression is upregulated or downregulated in cancer patients, demonstrating that ZNFs may act both as tumour suppressors or oncogenes. Furthermore, the functions of several ZNFs seem to be selective for specific tumours. Thus, the design of drugs that target specific ZNFs to avoid or restore abnormal expression of these proteins could be one of the most important challenges in the near future. Moreover, given the high specificity in terms of function and expression of some ZNFs for some tumours, it could be useful to exploit this class of proteins as prognostic factors.

**ACKNOWLEDGEMENTS**

This work has been supported by the Medical Research Council, UK; grants from Associazione Italiana per la Ricerca contro il Cancro (AIRC): AIRC 2014 IG15653 (to GM), AIRC Sxmille MCO9979 (to GM), Fondazione Roma malattie Non trasmissibili Cronico-Degenerative (NCD) Grant (to GM).

**COMPETING INTERESTS**

The authors declare no conflict of interest.

**PUBLISHER’S NOTE**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**REFERENCES**

1. Gibson TJ, Postma JP, Brown RS, Argos P. A model for the tertiary structure of the 28 residue DNA-binding motif (‘zinc finger’) common to many eukaryotic transcriptional regulatory proteins. Proteins Eng 1988; 2: 209–218.
2. Warna KE, Churchill ME, Tullius TD, Brown DD. Mapping functional regions of transcription factor TFIIIA. Mol Cell Biol 1988; 8: 1684–1696.
Huang F, Abmayr SM, Workman JL. Regulation of KAT6 acetyltransferases and cell death. Cell Death Biochem Biochem Commun 2011; 43(1): 58–61.

Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Genenames.org: the database resources. Nucleic Acids Res 2015; 43(Database issue): D1079–D1085.

Nunez N, Clifton MM, Funnell AP, Artuz C, Hallal S, Quinlan KG. The multi-domain Cys2His2-type zinc finger in health and disease. Trends Genet 2017; 33(10): 519–527.

Hossain MA, Barrow JJ, Shen Y, Haq MI, Bungert J. Artificial zinc-finger DNA binding domains: versatile tools for genome engineering and modulation of gene expression. J Cell Biochem 2015; 116: 2435–2444.

Malgieri G, Palmieri M, Russo L, Fattorusso R, Pedone PV, Isernia C. The prokaryotic zinc-finger: structure, function and comparison with the eukaryotic counterpart. FEBS J 2015; 282: 4480–4496.

Eom KS, Cheong JS, Lee SJ. Structural analyses of zinc finger domains for specific interactions with DNA. J Microbiol Biotechnol 2016; 26: 2019–2029.

Zhang W, Xu C, Bian C, Tempel W, Csombot L, Mackenzie F et al. Crystal structure of the Cys2His2-type zinc finger domain of human DPF2. Biochem Biophys Res Commun 2011; 413: 58–61.

Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Genenames.org: the database resources. Nucleic Acids Res 2015; 43(Database issue): D1079–D1085.

Nunez N, Clifton MM, Funnell AP, Artuz C, Hallal S, Quinlan KG. The multi-domain Cys2His2-type zinc finger in health and disease. Trends Genet 2011; 10: 315–320.

Turner CE, Miller JT. Primary sequence of paxillin contains putative SH2 and SH3 domain binding motifs and multiple LIM domains: identification of a vinculin and pp125Fak-binding region. J Cell Sci 1994; 107(Pt 6): 1583–1591.

Dubrovskyi O, Tian X, Poroyko V, Yakubov B, Birukova AA, Birukov KG. Identification of paxillin domains interacting with beta-catenin. FEBS Lett 2012; 586: 2294–2299.

Smith MA, Blankman E, Deakin NO, Hoffman LM, Jensen CC, Turner CE et al. LIM domains target actin regulators paxillin and zyxin to sites of stress fiber strain. PLoS One 2013; 8: e69378.

Wang J, Wang H, Wang LY, Cai D, Duan Z, Zhang Y et al. Silencing the epigenetic silencer KDM4A for TRAIL and DRS induced inactivation and antitumor therapy. Cell Death Differ 2016; 23: 1886–1896.

Cao LL, Wei F, Du Y, Song B, Wang D, Chen C et al. ATM-mediated KDM2A phosphorylation is required for the DNA damage repair. Oncogene 2016; 35: 301–313.

Huang F, Abmayr SM, Workman JL. Regulation of KAT6 acetyltransferases and their roles in cell cycle progression, stem cell maintenance, and human disease. Mol Cell Biol 2016; 36: 1900–1907.

Elton L, Carpenter L, Verhelst K, Staal J, Beyaert R. The multifaceted role of the E3 ubiquitin ligase HOIL1: beyond linear ubiquitination. Immuno Rev 2015; 266: 208–221.

Asfahl W, Abraham I, Alhosin M, Zaayter L, Ouarahni K, Papin C et al. The epigenetic integrator UHRF1: on the road to become a universal biomarker for cancer. Oncotarget 2017; 8: 51946–51962.

Fu M, Blackshear PJ. RNA-binding proteins in immune regulation: a focus on CCCH zinc fingers. Nat Rev Immunol 2017; 17: 130–143.

Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ. Nucleo-cytoplasmic shuttling of the hdmi oncogene regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J 1998; 17: 554–564.

Tao W, Levine AJ. Nucleocyttoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci USA 1996; 93: 3077–3080.

Uhlen M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A et al. Proteomics: tissue-based map of the human prostate. Science 2015; 347: 1260941.

Peng Y, Clark KJ, Campbell JM, Panetta MR, Guo Y, Ekker SC. Making designer mutants in model organisms. Development 2014; 141: 4042–4054.

Bibikova M, Beumer K, Trautman JK, Carroll D. Enhancing gene targeting with designed zinc finger nucleases. Science 2003; 300: 764.

Umov FD, Miller JC, Lee YL, Beauseroir JM, Rock JM, Augustus S et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005; 435: 646–651.
66 Mistrik M, Bartek J. What a ‘Ku’incidence!: parallel discoveries of a new DNA repair protein, 53BP1.
67 Zhang L, Zhou Y, Cheng C, Cui H, Cheng L, Kong P. Loss of the C/EBP family of transcription factors is critical in GATA-mediated suppression in colorectal cancer.
68 Juncker-Jensen A, Romer J, Pennington CJ, Lund LR, Almholdt K. Spontaneous transformation in meta-stable multi-potential mouse embryonic stem cells.
69 LAMC2 enhances the paracrine-induced growtharrest. Cell Death Dis 2015; 6: e1947.
70 Dawson MI, Park JH, Chen G, Chao W, Dousman L, Waleh N. The ZBP-89 mRNA expression as a novel candidate biomarker of chordomalldiosis in esophageal squamous cell carcinoma. Oncology 2013; 87: 197–203.
71 Liu YW, Sun M, Xia R, Zhang EB, Liu XH, Zhang ZH et al. LINCHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. Cell Death Dis 2015; 6: e1802.
72 Herveckling H. The miR-34 family in cancer and apoptosis. Aging (Alanyi IV) 2015; 7: 1050–1065.
73 Zhang L, Zhou H, Cheng C, Li K, Zhang J, Li Y, Zhang L et al. A gene expression signature and frequently altered genes in esophageal squamous cell carcinoma. Am J Hum Genet 2015; 96: 597–611.
74 Agostini M, Knight RA. miR-34: from bench to bedside. Oncocarget 2015; 4: 872–881.
75 Diaz R, Druett-Mathes S, Wu X, Bader DL, Olin E et al. Zinc finger proteins in cancer progression. J Biomed Sci 2016; 23: 53.
76 Kim SH, Kim HS, Lee SW, Shin JH, Seo JH et al. Cell Death Differ 2015; 22: 1517–1525.
77 Fidalgo M, Faiola F, Pereira CF, Ding J, Saunders A, Gningold J et al. The role of 53BP1 protein in homology-directed DNA repair: things get a bit complicated.
78 Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X et al. The miR-34 family in cancer and apoptosis. Hum Mol Genet 2015; 24: 370–380.
79 Oka H, Ito M, Hasezawa S, Nomura T, Nakamura M et al. The zinc finger protein ZNF750 is a novel candidate biomarker of neurourothelial carcinoma. Clin Cancer Res 2015; 21: 6180–6191.
80 Tang CH, Yamamoto A, Lin YT, Fong YC, Tan TW. Zinc finger proteins in cancer. J Biomed Sci 2016; 23: 175–186.
81 Zhang JS, Gong A, Young CY. ZNF185, an actin-cytoskeleton-associated growth inhibitor. J Cell Sci 2007; 120: 949–960.
82 Taniuchi T, Mortensen ER, Ferguson A, Greenen J, Merchant JL. Overexpression of ZFP-89, a zinc finger DNA binding protein, in gastric cancer. Biochem Biophys Res Commun 1997; 233: 154–160.
Zinc-finger proteins in health and disease
M Cassandri et al

108 Lindstrom MS, Jin A, Deisenroth C, White Wolf G, Zhang Y. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol Cell Biol 2007; 27: 1056–1068.

109 Wu W, Xu C, Ling X, Fan C, Buckley BP, Chernov MV et al. Targeting RING domains of Mdm2-MdmX E3 complex activates apopotic arm of the p53 pathway in leukemia/lymphoma cells. Cell Death Dis 2015; 6: e2035.

110 Wang S, Zhao Y, Aguilar A, Bernard D, Yang CY. Targeting the MDM2-p53 protein–protein interaction for new cancer therapy: progress and challenges. Cold Spring Harbor Perspect Med 2017; 7: pii: a026245.

111 Haupt S, Buckley D, Pang JM, Panimaya J, Lott SJ, Gamell C et al. Targeting Mdmx to treat breast cancers with wild-type p53. Cell Death Dis 2015; 6: e1821.

112 Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15: 178–196.

113 Zhang P, Sun Y, Ma L. ZEB1 at the crossroads of epithelial–mesenchymal transition, metastasis and therapy resistance. Cell Cycle 2015; 14: 481–487.

114 Li X, Gao D, Wang H, Li X, Yang J, Yan X. Negative feedback loop between p66Shc and ZEB1 regulates fibrotic EMT response in lung cancer cells. Cell Death Dis 2015; 6: e1708.

115 Shi Y, Sawada J, Sui G, Affar el B, Whetstine JR, Lan F et al. Coordinated histone modifications mediated by a CBP co-repressor complex. Nature 2003; 422: 735–738.

116 Sanchez-Tillo E, Lazaro A, Torrent R, Cuatrecasas M, Vaquero EC, Castells A et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene 2010; 29: 3490–3500.

117 Thakur AK, Nigri J, Lac S, Leja J, Bresly C, Berthezene P et al. Tap73 loss favors Smad-independent TGF-beta signaling that drives EMT in pancreatic ductal adenocarcinoma. Cell Death Differ 2016; 23: 1359–1370.

118 Heldin CH, Vanlandewijck M, Moustakas A. Regulation of EMT by TGF-beta in cancer. FEBS Lett 2012; 586: 1959–1970.

119 Zhang GJ, Zhou T, Tian HP, Liu ZL, Xiao SS. High expression of ZEB1 correlates with liver metastasis and poor prognosis in colorectal cancer. Oncol Lett 2013; 5: 564–568.

120 Shen A, Zhang Y, Yang H, Xu R, Huang G. Overexpression of ZEB1 relates to metastasis and invasion in osteosarcoma. J Surg Oncol 2012; 105: 830–834.

121 Lakoma A, Barbieri E, Agarwal S, Jackson J, Chen Z, Kim Y et al. The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type non-small cell leukemia. Cell Death Discov 2015; 1.

122 Kim ES, Shohet JM. Reactivation of p53 via MDM2 inhibition. Cell Death Dis 2015; 6: e1936.

123 Spaderna S, Schmalhofer O, Wahibbi M, Dimmler A, Bauer K, Sultan A et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 2008; 68: 537–544.

124 Liu Y, Zhang N, Wang Y, Xu M, Liu N, Pang X et al. Zinc finger E-box binding homeobox 1 promotes invasion and bone metastasis of small cell lung cancer in vitro and in vivo. Cancer Sci 2012; 103: 1420–1428.

125 Markowitz JA, Tinkle MB, Fischbeck KH. Spinal muscular atrophy. Cold Spring Harbor Perspect Med 2011; 33: 12–20.

126 Lefebvre S, Burglen L, Rebullot S, Clermont O, Burlet P, Viollet L et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80: 155–165.

127 Helmlken C, Hofmann Y, Schoenen F, Oprea G, Raschke H, Rudnick-Schoneborn S et al. Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1. Hum Genet 2003; 114: 11–21.

128 Ahmad S, Wang Y, Shaik GM, Burghes AH, Gangwani L. The zinc finger protein ZPR1 is a potential modifier of spinal muscular atrophy. Hum Mol Genet 2012; 21: 2745–2758.

129 Pao PC, Huang NK, Liu YW, Yeh SH, Lin ST, Hsieh CP et al. A novel RING finger protein, Znf179, modulates cell cycle exit and neuronal differentiation of P19 embryonal carcinoma cells. Cell Death Differ 2011; 18: 1791–1804.

130 Ko CY, Chang LH, Lee YC, Sterneck E, Cheng CP, Chen SH et al. CCAAT/enhancer binding protein delta (CEBPdelta) elevating PTX3 expression inhibits macrophage-mediated phagocytosis of dying neuron cells. Neurobiol Aging 2012; 33: 422 e111–422 e425.